LLY Stock Analysis: Lilly(Eli) & Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialize
- Latest close
- $1,157.08
- 20-day change
- -0.25%
- Trend state
- BULLISH
- Classification
- Healthcare · Drug Manufacturers - General
Market context
Lilly(Eli) & Company moved -0.25% over the latest 20-session window. BullRecon currently classifies the broader setup as BULLISH.
Latest report
The latest cached company filing period (FY2025 · $65.2B revenue · $20.6B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Growth is currently the strongest dimension at 6.0/6, while Value is the lowest at 2.7/6. Scores are comparative research signals, not forecasts.